Heat shock protein 90 (Hsp90) stabilizes a variety of proteins required for cancer cell survival and has been identified as a promising drug target for cancer treatment. To date, several Hsp90 inhibitors have entered into clinical trials, but none has been approved for cancer therapy yet. Thus, exploring new Hsp90 inhibitors with novel mechanisms of action is urgent. In the present study, we show that Y-632, a novel pyrimidine derivative, inhibited Hsp90 in a different way from the conventional Hsp90 inhibitor geldanamycin. Y-632 induced degradation of diverse Hsp90 client proteins through the ubiquitin-proteasome pathway, as geldanamycin did; however, it neither directly bound to Hsp90 nor inhibited Hsp90 ATPase activity. Y-632 inhibited Hsp90 function mainly through inducing intracellular thiol oxidation, which led to disruption of the Hsp90-Hsp70 ⁄ Hsp90 organizing protein complex and further induced cell adhesion inhibition, G 0 ⁄ G 1 cell cycle arrest, and apoptosis. Moreover, Y-632 efficiently overcame imatinib resistance mediated by Bcr-Abl point mutations both in vitro and in vivo. We believe that Y-632, acting as a novel small-molecule inhibitor of the Hsp90-Hsp70 ⁄ Hsp90 organizing protein complex, has great potential to be a promising Hsp90 inhibitor for cancer therapy, such as for imatinib-resistant leukemia.
H eat shock protein 90 is a ubiquitously expressed and highly conserved ATPase-dependent molecular chaperone. By forming a large multiprotein complex in cohort with diverse co-chaperones such as Hsp70, Cdc37, and Hop, Hsp90 plays an essential role in post-translational conformational maturation, stabilization, and activation of a broad range of client proteins, most of which are directly involved in tumor growth and survival. (1, 2) Thus, inhibition of Hsp90 leads to degradation of these proteins and ultimately causes cancer cell growth arrest and apoptosis. (3) To date, several Hsp90 inhibitors have been under development and are being evaluated as a possible strategy for cancer treatment. (4, 5) In 1999, 17-AAG, a derivative of the first Hsp90 inhibitor GA, entered into clinical trials. (6) Since then, 16 distinct Hsp90 inhibitors, including natural product derivatives and fully synthetic small molecules, have been selected for clinical studies. (7) (8) (9) These compounds all bind to the Nterminal ATP ⁄ ADP binding site of Hsp90 and abolish its ATPase activity. Despite the fact that a few Hsp90 inhibitors are in clinical trials, none has been approved for cancer therapy. (10) Based on high throughput drug screening, we have found a pyrimidine derivative, Y-632, to be a novel Hsp90 inhibitor with a structure distinct from current ones. In the present study, we show that Y-632 inhibited cell adhesion, caused cell cycle arrest, and apoptosis. Y-632 caused degradation of Hsp90 client proteins through inducing intracellular thiol oxidation and thus disrupted Hsp90-Hop interaction in an ATPase-independent mechanism. Moreover, Y-632 efficiently overcame imatinib resistance mediated by Bcr-Abl point mutations both in vitro and in vivo. Therefore, it is believed that Y-632 is a novel and promising Hsp90 inhibitor for cancer therapy.
Sciences (Shanghai, China). Imatinib mesylate was obtained from Selleck Chemicals (Houston, TX, USA). Geldanamycin was obtained from Sangon Biotech (Shanghai, China). MG132, proteasome inhibitor I (PS341), chloroquine, MDL28170, monobromobimane, SRB, MTT, and antibodies against b-tubulin and insulin-like growth factor 1 receptor were purchased from Sigma-Aldrich (St. Louis, MO, USA). Antibodies against human epidermal growth factor receptor-2, GAPDH, EGFR, c-Met, Akt, phospho-Akt (Ser473), Cdk4, Cdk6, p85, poly-(ADP-ribose) polymerase, caspase 8, caspase 9, Hop, Cdc37, Erk1 ⁄ 2, and phospho-Erk1 ⁄ 2 (Thr202 ⁄ Tyr204) were purchased from Cell Signaling Technology (Beverly, MA, USA). Antibodies against b-actin, Raf-1, p23, and caspase 3 were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies against Hsp90 and Bcr-Abl were from Abcam (Cambridge, UK). Anti-Hsp70 antibody was from Enzo Life Sciences (Farmingdale, NY, USA). Antiphosphotyrosine antibody (clone 4G10) was obtained from Millipore (Billerica, MA, USA).
Cell culture and treatment. Cell lines K-562, SK-BR-3, MCF7, A-431, and SNU-5 were obtained from ATCC (Manassas, VA, USA) and cultured according to instructions provided.
Western blot analysis and immunoprecipitation. Whole-cell lysates were prepared, separated by SDS-PAGE, and transferred to PVDF membranes. After incubation with primary and secondary antibody, immunoreactive proteins were detected using the enhanced chemiluminescence system from Thermo Fisher Scientific (Waltham, MA, USA).
For analysis of Triton-soluble and insoluble protein, Western blot was carried out essentially as described previously. (11) Briefly, cells were lysed in Triton X-100 lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 20 lg ⁄ mL leupeptin, 2 mM sodium orthovanadate, 1 mM PMSF, 5 mM sodium fluoride, and 5000 U ⁄ mL aprotinin) and the lysates were centrifuged, then the supernatants were collected as Triton-soluble fraction and the pellet (Triton-insoluble fraction) was lysed with 2% SDS in 50 mM Tris-HCl then boiled for 15 min.
For immunoprecipitation, whole-cell lysates were incubated with anti-Hsp90 antibody and protein G agarose (Pierce, Rockford, IL, USA). Then the levels of immunoprecipitated proteins were analyzed by Western blot. Detailed procedures were referred to a previous report. (12) Each photograph of Western blot analyses is from the same lysate and is representative of three separate experiments.
Colorimetric adhesion assay. The cell adhesion assay was carried out as described previously. (13) Drug-treated cells were added to 96-well plates that were precoated with 1% gelatin and incubated at 37°C for 3 h. Then detached cells were washed with PBS (pH 7.4) containing 0.05% Tween-20 and adhered cells were analyzed using SRB assay.
Cell cycle analysis. The cell cycle distribution was measured by propidium iodide staining, a typical method for cell cycle analysis since the 1970s. (14) (15) (16) (17) (18) (19) Briefly, cells were fixed with ice-cold 70% ethanol overnight and stained with 50 lg ⁄ mL propidium iodide and 50 lg ⁄ mL RNase A. (20) The cell cycle was then measured by using a FACScan flow cytometer (BD Biosciences, San Jose, CA, USA) and analyzed with CellQuest Pro (BD Biosciences) and ModFit LT 3.0 software (Verity Software House).
Cell proliferation assay. Cells were incubated with various concentrations of drugs in 96-well plates and cultured for 72 h. Cell proliferation was determined by SRB assay for adherent cells or MTT assay for suspended cells as described previously. (20, 21) Colorimetric determination of ATPase activity. Inhibition of yeast Hsp90 ATPase activity was detected by malachite green assay. (22) In brief, 0.2 mg ⁄ mL yeast Hsp90 was incubated with drugs in assay buffer (100 mM Tris-HCl [pH 7.4], 20 mM KCl, and 6 mM MgCl 2 ) containing 1 mM ATP (Sigma-Aldrich). After incubation at 37°C for 4 h, malachite green reagent was added, followed by the injection of 34% sodium citrate. The mixture was then incubated for 15 min at room temperature and the absorbance at 620 nm was measured using a Synergy H4 Hybrid reader (BioTek, Winooski, VT, USA).
Surface plasmon resonance analysis. In general, SPR was carried out as described previously. (23) First, the CM5 sensor chip was balanced with running buffer (10 mM HEPES [pH 7.4], 0.15 M KCl, and 0.001% Tween-20) for 10 min at 25°C to prevent non-specific binding of proteins to the capillaries of the Biacore 3000 (GE Healthcare, Cleveland, OH, USA) instrument. Then human recombinant Hsp90a (150 lg ⁄ mL in 10 mM sodium acetate [pH 4.3]) was immobilized on the CM5 chip surface. Non-covalently bound Hsp90 was quenched with 1 M ethanolamine. Compounds were injected from lowest to highest concentrations at a flow rate of 30 lL ⁄ min. An additional 3 min was needed to monitor the dissociation of the compound-protein complex.
Luciferase refolding assay. Luciferase refolding assay was carried out as described previously. (24) Rabbit reticulocyte lysate (Promega, Madison, WI, USA) was incubated with DMSO (control) or drugs for 30 min at 37°C. Firefly luciferase (Sigma-Aldrich) was denatured for 10 min at 41°C and refolding reaction was initiated after drug-pretreated RRL was injected. The reaction system was incubated at 25°C for 2 h and then the luciferase activity was detected.
Detection of intracellular free thiol levels. Monobromobimane was used to determine intracellular free thiol levels. (25) After drug treatment, cells were collected, plated into 96-well plates, and then loaded with 100 lM monobromobimane for 30 min in the dark. The fluorescence was detected with excitation and emission wavelengths at 390 and 460 nm, respectively.
In vivo study. All animal experiments were carried out in accordance with the Institutional Animal Care and Use Committee guidelines at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Female nude mice (Balb ⁄ cAnude, 5-6 weeks old) were purchased from Shanghai SLAC Laboratory Animal Co., Ltd (Shanghai, China). Cells (32D-WT or 32D-T315I, 10 9 10 7 ) were implanted s.c. into nude mice. After 48 h of inoculation, mice were randomized into four groups with 7-11 mice each group. The animal number required in each group was based on a comprehensive review of published reports (26, 27) and the 3R (reduction, refinement, and replacement) principles of the Institutional Animal Care and Use Committee guidelines at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Mice were then treated with vehicle (60% PEG-400, i.p.), Y-632 (7 mg ⁄ kg ⁄ day and 10 mg ⁄ kg ⁄ day, i.p.), or imatinib mesylate (200 mg ⁄ kg ⁄ day, p.o.) for a total of 16 days. Tumor volume was calculated as width 2 9 length 9 0.5 and body weight was monitored as an indicator of general health.
For the pharmacodynamics study, mice bearing tumors received a single i.p. of 10 mg ⁄ kg Y-632 or vehicle and then tumor tissues were collected at 8 h post-dosing. Tumor samples were homogenized in RIPA buffer and analyzed by Western blot.
Statistical analysis. Results of repetitive experiments are presented as mean AE SD or mean AE SEM. A two-tailed Student's t-test was used for comparison of treatment versus control groups. Statistical analysis was carried out using GraphPad Prism 6 software (GraphPad Software, Inc., San Diego, CA, USA).
Results
Y-632 induces degradation of diverse Hsp90 client proteins through ubiquitin-proteasome pathway. In searching for novel Hsp90 inhibitors, a panel of pyrimidine derivatives was rationally designed from the structure-activity relationships investigation and structure optimization based on a hit compound Y-498 (Fig. 1a) , which has been identified as an Hsp90 inhibitor. The derivatives were screened, based on their effects on Hsp90 client proteins and Hsp70 level, and Y-632 was ultimately identified (Fig. 1a) . In Bcr-Abl-overexpressing leukemia K-562 cells, Y-632 reduced different Hsp90 client proteins levels (Bcr-Abl, Raf-1, Akt, and Cdk6) in a time-and dose-dependent manner (Fig. 1b) . Correspondingly, extensive elevation of Hsp70 was observed (Fig. 1b) . Y-632 also induced diverse Hsp90 client protein degradation and Hsp70 elevation in SK-BR-3, A-431, MCF7 and SNU-5 cells, which overexpress human epidermal growth factor receptor-2, EGFR, insulin-like growth factor 1 receptor, and c-Met, respectively (Fig. 1c) . Moreover, the protein level of non-Hsp90-dependent protein p85 was not altered. As a positive Hsp90 inhibitor, GA also significantly decreased Hsp90 client proteins and induced Hsp70 expression (Fig. 1b,c) .
Most Hsp90 inhibitors induce misfolded protein degradation through the ubiquitin-proteasome pathway. (28) Once proteins are misfolded and aggregated, their solubility will decrease. Being an appropriate detergent to distinguish proteins according to their solubility properties, Triton X-100 was used to increase the sensitivity of detection of proteins with low solubility. (29, 30) As shown in Figure 1(d) , the combination of Y-632 with proteasome inhibitors MG132 (31) or PS341 (32) induced significant elevation of ubiquitinated Raf-1 and Akt (insoluble fraction) both in K-562 and SK-BR-3 cells. In contrast, neither lysosome inhibitor chloroquine (33) nor calpain inhibitor MDL28170 (34) mimicked the same effect, indicating that Y-632 triggered degradation in a ubiquitin-proteasome-dependent manner. Taken together, Y-632 showed the same effect as Hsp90 inhibitor GA did, raising the possibility that it may be a potential Hsp90 inhibitor. (P < 0.01) and 14.9% (P < 0.0001) of control, respectively, whereas the equal effect was not observed with GA even up to 10 lM (Fig. 2a) , indicating that Y-632 potently inhibits tumor cell adhesion, in contrast to GA. Then we detected the effect of Y-632 on the cell cycle and cell apoptosis. Twenty-four hours of Y-632 treatment induced G 0 ⁄ G 1 cell cycle arrest in a dose-dependent manner in SK-BR-3, K-562, and A-431 cells, whereas GA arrested cells at G 2 phase (Fig. 2b) , as reported previously. (35) Furthermore, cell apoptosis was induced by prolonged Y-632 treatment (48 h), which was manifested by the concentration-dependent increase of cleaved caspase 8, decrease of procaspase 9 and procaspase 3, and cleavage of poly-(ADP-ribose) polymerase (Fig. 2c) . client proteins in tumor cells, (36) (37) (38) the concentration of Y-632 we used in this assay was up to 500 lM. As shown in Figure 3(a) , GA significantly abolished Hsp90 ATPase activity by 49% (P < 0.05) and 95% (P < 0.001) at 1 lM and 100 lM, respectively, but Y-632 had no significant effect on Hsp90 ATPase activity. Next, we used SPR assay to assess the affinity Results in (a,c) are shown as mean AE SD of at least three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. ,c) are shown as mean AE SD of at least three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Akt, protein kinase B; Cdk, cyclin-dependent kinase; Con, control.
Y-632 inhibits
of Y-632 to purified recombinant human full-length Hsp90a. In contrast to GA, Y-632 showed no interaction with Hsp90 even up to 10 lM (Fig. 3b) , indicating that Y-632 neither inhibits Hsp90 ATPase activity nor binds to Hsp90. Thus, we wondered whether Y-632 inhibited Hsp90 by damaging the superchaperone complex machinery. Luciferase refolding assay was used to examine the effect of Y-632 on the ability of RRL, which is abundant in Hsp90 and its co-chaperones, to refold thermally denatured firefly luciferase. As shown in Figure 3 (c), when treated with increasing concentrations of GA or Y-632, RRL showed reduced capability of refolding denatured luciferase to its native state, whereas the native luciferase activity was unaffected (data not shown), suggesting that Y-632 inhibits the Hsp90 super-chaperone complex. Next, we used immunoprecipitation assay to clarify which co-chaperone was involved. Significant downregulation of Hop was observed in 16 h Y-632-treated K-562 cells, while the total Hop protein level was unchanged.
Other co-chaperones such as Hsp70, Cdc37, and p23 were not affected (Fig. 3d) . Thus, it was indicated that Y-632 inhibits Hsp90 mainly by disturbing the interaction of Hsp90 and Hop.
Y-632 reduces intracellular thiol levels and thus leads to Hsp90 inhibition. Recently, researchers have reported that post-transcriptional modifications of Hsp90 such as phosphorylation and oxidation have multiple impacts on Hsp90 function. (39, 40) In addition, thiol-reactive small molecules can modify Hsp90's cysteine residues and further affect its function both in vitro and in vivo. (41, 42) With a thiol-reactive a, b-unsaturated bond structure, Y-632-induced Hsp90 complex oxidation was considered to be a possible mechanism of action. As shown in Figure 4 (a), when pre-incubated with thiol-containing antioxidants GSH or DTT, both Y632-induced Hsp90 client proteins (Bcr-Abl, Raf-1, Akt, Cdk4, Cdk6) degradation and Hsp70 elevation were reversed, suggesting that Y-632 probably inhibits Hsp90 through thiol oxidation. Next, we tested the intracellular thiol state after Y-632 treatment using monobromobimane, a reagent that forms fluorescent adducts after conjugated with thiol-containing molecules. Indeed, Y-632 significantly decreased thiol levels in K-562 cells in a time-and dosedependent manner. Four hours of treatment with 10 lM Y-632 resulted in almost 50% (P < 0.0001) decrease of total thiol levels (Fig. 4b) . Moreover, GSH and DTT both restored Y-632's inhibition of reticulocyte lysate to refold denatured luciferase, but not GA's (Fig. 4c) . The effect Y-632 on Hsp90-Hop interaction was also reversed by GSH and DTT (Fig. 4d) . These results indicate that Y-632 induces thiol oxidation, leading to Hsp90-Hop complex disruption and further Hsp90 inhibition.
Y-632 inhibits growth of imatinib-resistant cells both in vitro and in vivo. Imatinib resistance is a major impediment in chronic myelogenous leukemia therapy, and acquisition of point mutations in the kinase domain of Bcr-Abl is the major mechanism. (43) As Y-632 could induce Bcr-Abl degradation, we wondered whether it could overcome imatinib resistance induced by certain Bcr-Abl mutants. As shown in Figure 5(a) , imatinib inhibited the proliferation of 32D cells harboring wild-type Bcr-Abl (32D-WT), but had a much weaker effect on other cells expressing transforming Bcr-Abl mutants. In contrast, Y-632 showed nearly equivalent IC 50 values towards 32D cells bearing wild-type or mutant Bcr-Abl. Consistent with these results, Y-632 induced the degradation of Bcr-Abl, leading to phosphorylation inhibition of Bcr-Abl and downstream Akt and Erk1 ⁄ 2 in both 32D cell lines (Fig. 5b) .
The in vitro potential of Y-632 to overcome imatinib resistance prompted us to investigate its effect in vivo. T315I is the most resistant mutant of Bcr-Abl, (43) thus, we studied the in vivo efficacy of Y-632 in 32D-T315I xenografts. Y-632 (10 mg ⁄ kg ⁄ day) potently inhibited the growth of both 32D-WT and 32D-T315I tumors by 66.6% (P < 0.0001) and 77.1% (P < 0.001), respectively, whereas imatinib (200 mg ⁄ kg ⁄ day) had an inhibitory effect (63.6%, P < 0.0001) only on 32D-WT xenografts (Fig. 5c) . To further investigate whether Y-632-induced tumor growth inhibition was related to its effect on Bcr-Abl, we measured Bcr-Abl protein level in tumor tissues. As shown in Figure 5 (d), Y-632 reduced the expression of Bcr-Abl in both 32D-WT and 32D-T315I tumors. Taken together, these results indicate that Y-632 efficiently overcomes imatinib resistance induced by Bcr-Abl point mutations, such as the T315I mutation, both in vitro and in vivo.
Discussion
In this study, we investigated the antitumor activity and mechanisms of Y-632. Unlike the classical Hsp90 inhibitors, Y-632 neither directly bound to Hsp90 nor inhibited Hsp90 ATPase activity. Instead, it significantly induced thiol oxidation, thus disrupted Hsp90-Hop interaction and inhibited Hsp90 function. In addition, Y-632 potently overcame imatinib resistance both in vitro and in vivo. We believe that Y-632, as a novel Hsp90 inhibitor, has great potential to be further investigated.
Most Hsp90 inhibitors inhibit Hsp90 function by regulating its ATPase activity. (44) In recent years, increased efforts have focused on Hsp90 post-translational modifications, such as oxidation, which provide alternative ways for Hsp90 inhibition. (45, 46) Tubocapsenolide A, a novel withanolide, induces a decrease of intracellular thiol levels, causes direct thiol oxidation of Hsp90, triggers Hsp90 to form intermolecular disulfide bonds, and consequently leads to Hsp90 client protein degradation. (11) Mahanine, a carbazole alkaloid, induces thiol oxidation and disulfide linkage of Hsp90, leading to the disruption of Hsp90-Cdc37 interaction. (47) In this study, we showed that Y-632 also inhibited Hsp90 through thiol oxidation. However, the exact mechanism was different from those reported previously, as Y-632 inhibited Hsp90 mainly by disrupting Hsp90-Hop interaction. Why the same thiol oxidation results in diverse mechanisms of Hsp90 inhibition is not yet clear. As cellular oxidative metabolism is complex, it is likely that these compounds have distinct thiol-reactive groups, and different thiol-reactive groups may have distinct affinities towards diverse intracellular reductive groups, which may lead to oxidation of different molecules in cells and thus result in diverse mechanisms of Hsp90 inhibition. However, the specific mechanism needs to be further investigated.
Heat shock protein 90 requires diverse co-chaperones to form a super-chaperone complex for its function. (48) Therefore, targeting the interaction of Hsp90 and its co-chaperones may be an alternative way to achieve the outcomes of direct Hsp90 inhibition. (49) One exciting finding in our study is that Y-632 disrupts Hsp90-Hop interaction; Hop is one of the Hsp90 cochaperones and plays an essential role in transfecting unfolded polypeptide from Hsp70 to Hsp90. (50) In metastatic or drugresistant tumors such as breast, ovarian, and colon carcinomas, Hop is upregulated, indicating that it is associated with cancer biology. (51, 52) To date, only a few agents have been discovered to disrupt Hsp90-Hop interaction. C9, a small molecule identified by an AlphaScreen technology, disrupts Hsp90-Hop interaction by binding to the TPR2A domain of Hop. (53, 54) Our report shows that Y-632 disrupted Hsp90-Hop interaction through thiol oxidation, which is quite different from C9. Considering susceptible cysteine residues are largely located at the Hsp90 C-terminal, which has the binding site of Hop, (42, 55) we speculate that Y-632 may induce oxidation of these cysteine residues and finally interfere with the interaction of Hop and Hsp90. Further study is still warranted to find the exact mechanism.
Point mutations in kinases such as Bcr-Abl, c-Kit, and EGFR lead to kinase inhibitor resistance, which is a major obstacle of cancer therapy. (43, 56, 57) Y-632 could inhibit the growth of imatinib-resistant cells both in vitro and in vivo, indicating Y-632 might have clinical application in overriding drug resistance caused by mutated oncoproteins, such as Bcr-Abl T315I. In addition, considering the mechanism of Y-632 on Hsp90 inhibition was distinct from the conventional Hsp90 inhibitors, we suggest that the combination of Y-632 with conventional Hsp90 inhibitors might result in better antitumor efficacy, which may broaden Y-632's application. However, for better understanding of Y-632's pharmacological effect, the effects of Y-632 on normal hematopoietic cells need to be further investigated.
In conclusion, Y-632 disrupts Hsp90-Hop interaction, causes degradation of Hsp90 client proteins by inducing intracellular thiol oxidation, and exerts antitumor activity in vitro and in vivo. It is especially efficient at overcoming drug resistance caused by mutated oncoproteins, such as Bcr-Abl T315I. It is believed that Y-632 is a promising Hsp90 inhibitor with a novel mechanism, and has great potential to be further developed.
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